Assessment of Serologic Immunity to Diphtheria-Tetanus-Pertussis After Treatment of Korean Pediatric Hematology and Oncology Patients.
10.3346/jkms.2012.27.1.78
- Author:
Hyo Jin KWON
1
;
Jae Wook LEE
;
Nak Gyun CHUNG
;
Bin CHO
;
Hack Ki KIM
;
Jin Han KANG
Author Information
1. Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. kjhan@catholic.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Serologic Immunity;
Immunocompromised Children;
Diphtheria;
Tetanus;
Pertussis;
Vaccination
- MeSH:
Adolescent;
Age Factors;
Antibodies, Bacterial/blood/immunology;
Antineoplastic Agents/therapeutic use;
Child;
Child, Preschool;
Diphtheria/immunology/prevention & control;
Diphtheria-Tetanus-acellular Pertussis Vaccines/*immunology;
Female;
Hematologic Neoplasms/*diagnosis/drug therapy;
Humans;
Immunization, Secondary;
Lymphoma/diagnosis/drug therapy;
Male;
Neuroblastoma/diagnosis/drug therapy;
Sex Factors;
Tetanus/immunology/prevention & control;
Whooping Cough/immunology/prevention & control
- From:Journal of Korean Medical Science
2012;27(1):78-83
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of this study was to investigate the diphtheria-tetanus-pertussis antibody titers after antineoplastic treatment and to suggest an appropriate vaccination approach for pediatric hemato-oncologic patients. A total of 146 children with either malignancy in remission after cessation of therapy or bone marrow failure were recruited. All children had received routine immunization including diphtheria-tetanus-acellular pertussis vaccination before diagnosis of cancer. The serologic immunity to diphtheria, tetanus and pertussis was classified as: completely protective, partially protective, or non-protective. Non-protective serum antibody titer for diphtheria, tetanus and pertussis was detected in 6.2%, 11.6%, and 62.3% of patients, respectively, and partial protective serum antibody titer for diphtheria, tetanus and pertussis was seen in 37%, 28.1%, and 8.9% of patients. There was no significant correlation between the severity of immune defect and age, gender or underlying disease. Revaccination after antineoplastic therapy showed significantly higher levels of antibody for each vaccine antigen. Our data indicates that a large proportion of children lacked protective serum concentrations of antibodies against diphtheria, tetanus, and pertussis. This suggests that reimmunization of these patients is necessary after completion of antineoplastic treatment. Also, prospective studies should be undertaken with the aim of devising a common strategy of revaccination.
